Home / Pharmaceutical company intelligence
Pharmaceutical company intelligence

AMROS PHARMACEUTICALS

Pharmaceutical manufacturer · Karachi · Pakistan

Karachi pharmaceutical manufacturer producing branded medicines for local and export markets.

Sourced corporate profile Corporate identity fields are source-tracked; portfolio, price and competitor intelligence remains independently calculated by MedInfoBase.
Official website ↗ Official contact ↗
ShareSend this page
Evidence & freshness

What is sourced, and how recent is it?

Public-source corporate details
Latest regulatory-source observation22 Sep 2026Newest linked source record observed by MedInfoBase
Latest portfolio source check22 Sep 2026Latest source-check date across this published portfolio
Latest effective price date17 Aug 2026Newest effective date among published current price records
Corporate profile evidence4 sourcesCorporate source details checked 16 Aug 2026

Regulatory-source portfolio data and company-supplied/corporate profile fields are tracked separately. Company claim/verification status is separate from source quality. An unclaimed company can still have a fully official-source-observed portfolio.

Regulatory & corporate identity

Company profile

Public-source corporate details
Company type
Pharmaceutical manufacturer
Address
A-96, S.I.T.E. II, Super Highway, Karachi, Pakistan
Phone
+92 21 111 222 234
Official contact
Contact page ↗
Corporate source details checked
16 Aug 2026
Corporate profile completeness
88%
Source-linked licence identifiersShown as recorded in linked source rows; not a claim of current validity.
DML 000406 87 linked products · source seen 22 Sep 2026 View source ↗
Corporate profile source ledger Contact Page Url source ↗ Logo Source Url source ↗
Location intelligence

Company location

Google Maps
Location recorded

A sourced company location is recorded. Use the map link below for directions.

Open in Google Maps ↗
Intelligence snapshot

Portfolio at a glance

Not sales data · published MedInfoBase database view
Rx87public portfolio records represented
REG72unique registrations represented
IDX87indexed MedInfoBase presentations
SRC0additional source-observed presentations
R+0registry-only registrations
VER0registry-verified exact registrations
PKR82current validated price records
G37generic molecules in indexed catalogue
DF8dosage-form groups
TA11therapeutic areas
How to read these counts

RegistrationA unique regulatory registration number. One registration may have more than one strength/form/pack presentation.

PresentationA distinct medicine presentation, such as a particular strength, dosage form and pack.

IndexedA canonical MedInfoBase presentation that passed MedInfoBase identity and publication controls.

Source observedAn additional presentation observed in an official DRAP source but not counted as an indexed MedInfoBase presentation.

Registry onlyAn exact registry-verified registration not otherwise represented by an indexed or source-observed presentation.

Registry verifiedAn exact registration match found in an official DRAP registry source. This is evidence status, not a commercial ranking.

Data coverage

How complete is this profile?

Current price coverage94%
public portfolio presentations with a validated current price
Official-source coverage100%
products linked back to a source record
Unit-price parse coverage100%
priced packs safely normalized per unit
Comparable-market coverage92%
products with at least one like-for-like comparator
Therapeutic classification100%
products assigned to a broad therapeutic area
Visual intelligence

Downloadable company intelligence charts

Copy or download any chart as a presentation-ready PNG. Every exported chart keeps MedInfoBase attribution and the source company-profile URL.

Shareable intelligence

Therapeutic Portfolio Mix

Shows where the company portfolio is concentrated across broad therapeutic areas.

Therapeutic Portfolio MixAMROS PHARMACEUTICALSShare of current product presentations by broad therapeutic areaMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/amros-pharmaceuticalsGenerated 23 Sep 2026Anti-infectives62 · 71%Pain & musculoskeletal5 · 6%CNS & mental health4 · 5%Cardiovascular4 · 5%Gastrointestinal & hepatology4 · 5%Cross-therapeutic & anti-inflamma…2 · 2%Respiratory & allergy2 · 2%Other therapeutic areas4 · 5%Percentages are based on current product presentations in the MedInfoBase company portfolio.

Portfolio distribution, not sales or market-share data.

Shareable intelligence

Dosage Form Portfolio

Shows how the company portfolio is distributed across tablets, capsules, injections, liquids and other forms.

Dosage Form PortfolioAMROS PHARMACEUTICALSDistribution of current product presentations by normalized dosage formMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/amros-pharmaceuticalsGenerated 23 Sep 202687presentationsTablet31 · 36%Injection21 · 24%Suspension14 · 16%Capsule13 · 15%Syrup3 · 3%Drops2 · 2%Other forms3 · 3%Dosage-form wording is normalized for intelligence display; original source wording remains preserved in product records.

Counts are product presentations, not production or sales volumes.

Shareable intelligence

Equivalent Price Position

Shows whether safely comparable products are below, near or above the peer median unit price.

Equivalent Price PositionAMROS PHARMACEUTICALSCurrent company products compared with like-for-like equivalent medicines using normalized unit pricesMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/amros-pharmaceuticalsGenerated 23 Sep 202680comparable productsBelow peer median38 · 48%Near peer median30 · 38%Above peer median12 · 15%Company median price position-4.7%Lowest-price equivalents16Method: same generic + stated strength + dosage form + compatible unit basis; pack prices normalized per unit.

This is price-position intelligence, not sales, demand or market-share data.

Shareable intelligence

Closest Portfolio Competitors

Highlights other manufacturers with the greatest generic overlap with this company portfolio.

Closest Portfolio CompetitorsAMROS PHARMACEUTICALSCompanies with the largest number of shared generic medicines in the MedInfoBase databaseMedInfoBase • medinfobase.comSource profile: medinfobase.com/company/amros-pharmaceuticalsGenerated 23 Sep 2026Mediate Pharmaceutical Pvt Ltd29 shared78% overlapBosch Pharmaceuticals (Pvt) Ltd.28 shared76% overlapZafa Pharmaceutical Laboratories (P…26 shared70% overlapS.J & G. Fazul Ellahie (pvt) limite…23 shared62% overlapNeutro Pharma (Pvt.) Ltd.,22 shared59% overlapNovaMed Pharmaceuticals(Pvt.)Ltd22 shared59% overlapPortfolio overlap measures shared generics only; it is not a measure of market share, affiliation or sales competition.

Competitor ranking is based on shared generics in MedInfoBase, not commercial sales performance.

Portfolio intelligence

Therapeutic areas

Broad portfolio view

High-level clinical areas represented by this company’s current MedInfoBase portfolio.

Anti-infectives62 products · 71%
Pain & musculoskeletal5 products · 6%
CNS & mental health4 products · 5%
Cardiovascular4 products · 5%
Gastrointestinal & hepatology4 products · 5%
Cross-therapeutic & anti-inflammatory2 products · 2%
Respiratory & allergy2 products · 2%
Hematology & thrombosis1 products · 1%
Pharmacological detail

Drug classes

More specific view

More specific classes derived from the canonical generic and preserved curated classifications.

Third-generation cephalosporins13 products · 15%
Penicillin antibacterials8 products · 9%
Nitroimidazole anti-infectives8 products · 9%
Macrolide antibacterials7 products · 8%
Fluoroquinolone antibacterials6 products · 7%
Analgesics / NSAIDs5 products · 6%
Lincosamide antibacterials4 products · 5%
Proton pump inhibitors4 products · 5%
Formulation footprint

Dosage forms

Tablet31 products
Injection21 products
Suspension14 products
Capsule13 products
Syrup3 products
Drops2 products
Infusion2 products
Solution1 products
How MedInfoBase classifies the portfolio

MedInfoBase uses a two-level taxonomy. Therapeutic area is a broad portfolio category, while drug class is the more specific pharmacological or clinical class. Existing curated classifications are preserved. Blank records are assigned conservatively from the canonical generic name and, when available, ATC information. Multi-use medicines may be placed in a cross-therapeutic category rather than forced into a single indication.

Portfolio leaders

Deepest brand families

Ranked by registered presentations · not sales
#1 FlgeMetronidazole 5presentations 200 mg, 200 mg/5 mL, 400 mg · Tablet, Suspension #2 AmfastAmoxicillin 4presentations 125 mg/5 mL, 250 mg, 250 mg/5 mL, 500 mg · Suspension, Capsule #3 AmrocipCiprofloxacin 4presentations 200 mg/100 mL, 250 mg, 250 mg/5 mL, 500 mg · Infusion, Tablet, Suspension #4 AmzaxCefotaxime 4presentations 1 g, 2 g, 250 mg, 500 mg · Injection #5 ClavAmoxicillin + clavulanic acid 4presentations 125 mg/5 mL + 31.25 mg/5 mL, 250 mg/5 mL + 62.5 mg/5 mL, 500 mg + 125 mg, 875 mg + 125 mg · Suspension, Tablet #6 KygetaClindamycin 4presentations 150 mg, 150 mg/mL · Injection, Capsule
Price intelligence

Unit-price positioning vs equivalent products

Same generic + strength + form + unit basis
Below market median3848% of comparable products
Near market median30within ±5% of median
Above market median1215% of comparable products
Lowest-price equivalents16ties included
Company median price position -4.7% relative to the median unit price of like-for-like equivalent products.
Most competitively positioned examplesProducts with at least 3 market comparators
Aspirin 300 mgAcetylsalicylic acid (Aspirin) · Tablet · 1000's PKR 0.45/tablet-86.6% vs market median Phenobarbitone 30 mgPhenobarbital · Tablet · 1000's PKR 0.19/tablet-79.2% vs market median Phenobarbitone 30 mgPhenobarbital · Tablet · 60's PKR 0.33/tablet-63.6% vs market median Kygeta 150 mgClindamycin · Capsule · 50's PKR 6.28/capsule-56.7% vs market median Rycristyx 20 mgSimvastatin · Tablet · 10's PKR 20.85/tablet-55.4% vs market median
How MedInfoBase calculates price position

Only current prices with safely interpretable pack quantities are used. A product is compared only with the same generic, same stated strength, same dosage form and a compatible unit basis such as tablet, capsule, mL or gram. These are database-derived price comparisons, not sales or market-share estimates.

Competitive landscape

Portfolio overlap

Companies sharing the largest number of generics with this portfolio. This measures product overlap, not commercial performance.

Mediate Pharmaceutical Pvt Ltd236 products · 90 generics 29shared generics Bosch Pharmaceuticals (Pvt) Ltd.258 products · 74 generics 28shared generics Zafa Pharmaceutical Laboratories (Pvt) Ltd.245 products · 97 generics 26shared generics S.J & G. Fazul Ellahie (pvt) limited.193 products · 68 generics 23shared generics Neutro Pharma (Pvt.) Ltd.,210 products · 97 generics 22shared generics NovaMed Pharmaceuticals(Pvt.)Ltd187 products · 62 generics 22shared generics
Regulatory & price activity

Observed database signals

Indexed registration numbers72Distinct registrations among indexed, published, presentation-validated products only
Verified price observations168
Products with a verified price87
Products with multiple price observations81
Source records with multiple versions86
Latest portfolio source check22 Sep 2026
Latest effective price date17 Aug 2026
Latest source observation22 Sep 2026

These dates describe records observed by MedInfoBase. They should not be interpreted as product launch dates or sales activity.

Company medicine portfolio

Medicine portfolio

72 unique registration(s) · 87 indexed presentation(s)

This unified portfolio keeps three evidence lanes distinct: indexed MedInfoBase presentations, additional source-observed presentations, and registry-only registrations that are not otherwise represented. A registration number is not the same thing as a presentation, and source-observed rows are not counted as indexed. Source-only rows with a strength/form/pack contradiction remain visible as evidence but the conflicting field is held for normalization.

Reset
BrandGenericStrengthFormPackRegistrationSource-listed priceUnit pricePrice position
Amfast Amoxicillin 500 mg Capsule 100's 019370 PKR 1,995.43 PKR 19.95/capsule Near median
Amfast Amoxicillin 125 mg/5 mL Dry suspension 60ml 019371 PKR 91.49 PKR 1.52/mL 7% above median
Amfast Amoxicillin 250 mg/5 mL Dry suspension 60mL 061648 PKR 134.34 PKR 2.24/mL 7% above median
Amfast Amoxicillin 250 mg Capsule 10×10's 061649 PKR 1,129.16 PKR 11.29/capsule Near median
Amoxazol Sulfamethoxazole + Trimethoprim 200 mg + 40 mg / 5 mL Suspension 50ml 019386 PKR 34.11 PKR 0.68/mL 9% below median
Amrocip Ciprofloxacin 250 mg Tablet 10's 058108 PKR 227.66 PKR 22.77/tablet 10% below median
Amrocip Ciprofloxacin 500 mg Tablet 10's 058109 PKR 407.89 PKR 40.79/tablet Near median
Amrocip Ciprofloxacin 200 mg/100 mL IV infusion 100mL 070526 PKR 227.66 PKR 2.28/mL Near median
Amrocip Ciprofloxacin 250 mg/5 mL Dry suspension 60ml 070768 PKR 303.55 PKR 5.06/mL Near median
Amrofen Ibuprofen 200 mg Tablet 500's 001965 PKR 1,242.09 PKR 2.48/tablet 10% above median
Amrofen Ibuprofen 400 mg Tablet 250's 019377 PKR 980.18 PKR 3.92/tablet 12% above median
Amrozee Azithromycin 500 mg Tablet 6's 104294 PKR 474.60 PKR 79.10/tablet 7% below median
Amrozee Azithromycin 250 MG Capsule 6's 104296 PKR 264.05 PKR 44.01/capsule 11% below median
Amrozee Azithromycin 250 mg Tablet 6's 107793 PKR 258.86 PKR 43.14/tablet 8% below median
Amrozee Granules for Azithromycin 200 mg/5 mL Oral suspension 15ml 104295 PKR 284.76 PKR 18.98/mL 5% below median
Amrozolin Cefazolin 1 g Injection 1's 100476 PKR 184.66 PKR 184.66/vial/unit 13% below median
Amzax Cefotaxime 250 mg Injection 1's 100463 PKR 105.46 PKR 105.46/vial/unit Near median
Amzax Cefotaxime 500 mg Injection 1's 100464 PKR 158.94 PKR 158.94/vial/unit Near median
Amzax Cefotaxime 1 g Injection 1's 100465 PKR 285.89 PKR 285.89/vial/unit Near median
Amzax Cefotaxime 2 g Injection 1's 100466 PKR 430.25 PKR 430.25/vial/unit 6% below median
Aspirin Acetylsalicylic acid (Aspirin) 300 mg Tablet 1000's 019395 PKR 446.86 PKR 0.45/tablet 87% below median
Clav Amoxicillin + clavulanic acid 125 mg/5 mL + 31.25 mg/5 mL Dry suspension 60mL 058100 PKR 172.56 PKR 2.88/mL No comparator
Clav Amoxicillin + clavulanic acid 250 mg/5 mL + 62.5 mg/5 mL Dry suspension 60mL 058101 PKR 271.00 PKR 4.52/mL No comparator
Clav Amoxicillin + clavulanic acid 500 mg + 125 mg Tablet 6's 061865 PKR 244.36 PKR 40.73/tablet Near median
Clav Amoxicillin + clavulanic acid 875 mg + 125 mg Tablet 6's 061866 PKR 309.22 PKR 51.54/tablet Near median
Dexamethasone Dexamethasone 4 mg Injection 25×1ml 020304 PKR 461.95 PKR 18.48/mL Near median
Dexamethasone Dexamethasone 0.5 mg Tablet 1000's 021788 PKR 531.99 PKR 0.53/tablet Near median
Diazepam Diazepam 10 mg Tablet 30's 108734 PKR 93.39 PKR 3.11/tablet 38% above median
Doxycycline Doxycycline 100 mg Capsule 100's 019379 PKR 1,007.18 PKR 10.07/capsule 28% above median
Doxycycline Doxycycline 100 mg Capsule 1's 019379 PKR 10.49 PKR 10.49/capsule 34% above median
EEVAN Lorazepam 2 mg Tablet 100's 108738 PKR 86.13 PKR 0.86/tablet 47% below median
Falcigo Artemether 80 mg Injection 1mL×6's 067637 PKR 1,138.31 PKR 189.72/mL 7% above median
Flge Metronidazole 200 mg Tablet 20 x 10's 118247 PKR 246.08 PKR 1.23/tablet 43% below median
Flge Metronidazole 400 mg Tablet 20's 118248 PKR 36.91 PKR 1.85/tablet 39% below median
Flge Metronidazole 400 mg Tablet 100's 118248 PKR 184.56 PKR 1.85/tablet 39% below median
Flge Metronidazole 400 mg Tablet 20 x 10's 118248 PKR 369.13 PKR 1.85/tablet 39% below median
Flge Metronidazole (Benzoate) 200 mg/5 mL Suspension 90mL 118249 PKR 59.06 PKR 0.66/mL 33% below median
Flge Metronidazole 200 mg/5 mL Suspension 120ml 118249 PKR 73.83 PKR 0.62/mL 33% below median
Flge Metronidazole (Benzoate) 200 mg/5 mL Suspension 60ml 118249 PKR 39.37 PKR 0.66/mL 33% below median
Furime Cefuroxime 250 mg Injection 1's 100474 PKR 51.70 PKR 51.70/vial/unit Near median
Furime Cefuroxime 750 mg Injection 1's 112434 PKR 115.84 PKR 115.84/vial/unit 39% below median
Furime Cefuroxime 1.5 g Injection 1's 112435 PKR 192.12 PKR 192.12/vial/unit 45% below median
Gentamycin Gentamicin 0.30% Eye/ear drops 10ml 019368 PKR 36.29 PKR 3.63/mL No comparator
Gentamycin Gentamicin 0.3% Eye/Ear drops 5ml 019368 PKR 72.53 PKR 14.51/mL No comparator
Gentamycin Gentamicin 80 mg/2 mL (40 mg/mL) Injection 1×2ml 021785 PKR 49.06 PKR 24.53/mL No comparator
Hybrid Hydroxychloroquine 200 mg Tablet 5x10's 101315 PKR 830.97 PKR 16.62/tablet 15% above median
Hybrid Hydroxychloroquine 200 mg Tablet 3x10's 101315 PKR 498.58 PKR 16.62/tablet 15% above median
Kelsey Cetirizine 5 mg/5 mL Oral solution 60mL 118251 PKR 33.22 PKR 0.55/mL 41% below median
Kelsey Cetirizine 10 mg Tablet 10's 118252 PKR 48.64 PKR 4.86/tablet 40% below median
Klarim Clarithromycin 125 mg/5 mL Dry suspension 60ml 058105 PKR 423.07 PKR 7.05/mL Near median
MedInfoBase company-intelligence methodology

This page is generated from MedInfoBase medicine, generic, company, price and official-source records. Unverified third-party discovery records are retained internally for coverage auditing and are not published as company registrations. Portfolio leaders are ranked by presentation depth, not sales. Price-position metrics are calculated from current official-source prices normalized to compatible units and compared only against like-for-like products with the same generic, stated strength and dosage form.

Not currently included: sales volume, revenue by brand, market share, prescription volume or best-selling rankings. MedInfoBase will display those only when supported by a defensible licensed, public or company-verified source.

Cite this record

Manufacturer record
MedInfoBase. (2026). AMROS PHARMACEUTICALS — registered product portfolio in Pakistan [Data set]. MedInfoBase. Retrieved September 23, 2026, from https://medinfobase.com/company/amros-pharmaceuticals/
Download .RIS Download .BIB EndNote, Zotero, Mendeley, RefWorks

Records change over time. Please cite the access date so readers can locate the version you used.